⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

November 11, 2025Urology PracticeOpen Access

Patient-reported outcomes following UGN-102 treatment in low-grade intermediate-risk non-muscle invasive bladder cancer: An analysis of three clinical trials

Charles C. Peyton Max Kates Anagha Nadkarni Rahul Dhanda Nikky Ugwuoke Victoria Tsurutis Brent Burger L. Veronica Lee Michael J. Louie Tom Burke Angela M. Stover

View Full Paper

Ask AI

Bookmark

Share

Abstract

In these analyses, patients with LG-IR-NMIBC receiving UGN-102 did not report worsening QoL, functioning, or symptom burden, supporting its use as a nonsurgical treatment for LG-IR-NMIBC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Peyton et al. (2025) studied this question.

synapsesocial.com/papers/69252ea3c0ce034ddc35671a https://doi.org/10.1097/upj.0000000000000917

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION TrialHuman Clinical Trial · 2026
2Patient experiences with UGN-102 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC): Insights for shared decision making.Cohort Study · 2026
3UTOPIA: A phase 3 trial of UGN-103, an intravesical mitomycin reverse thermal hydrogel, in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.Human Clinical Trial · 2026
4Response to primary chemoablation with UGN-102 in different EOTRC risk groups.Human Clinical Trial · 2026
5Assessing responses to UGN-102 across EORTC recurrence score groups in patients with recurrent low-grade intermediate-risk NMIBC (ENVISION trial).Human Clinical Trial · 2026

More related papers

Pharmacokinetics of UGN‑102, an investigational mitomycin‑containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer2025
Treatment of recurrent non-muscle invasive bladder cancer with UGN-301 (zalifrelimab) alone and in combination: A phase 1 dose escalation study.2026
Noninvasive early detection and recurrence monitoring for non-muscle-invasive bladder cancer via urine tumor DNA.2024

More from Urology Practice

Timing of FDA-Defined Adequate BCG Therapy and Oncologic Outcomes in High-Risk Non-Muscle-Invasive Bladder CancerFri,
Open Surgery in the Robotic Era: National Trends and Training Implications from Two Decades of American Board of Urology Case LogsFri,